Publications

BibTex format

@article{Mulla:2023:10.1111/dme.15053,
author = {Mulla, K and Farag, S and Moore, B and Matharu, S and Young, K and Larkin, J and Popat, S and Morganstein, DL},
doi = {10.1111/dme.15053},
journal = {Diabetic Medicine},
pages = {1--10},
title = {Hyperglycaemia following immune checkpoint inhibitor therapy-Incidence, aetiology and assessment},
url = {http://dx.doi.org/10.1111/dme.15053},
volume = {40},
year = {2023}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - AimsWe systematically studied the presence of hyperglycaemia during treatment with Immune Checkpoint Inhibitors (ICPI) for cancer, in those with and without diabetes at baseline, and determined the cause of new-onset hyperglycaemia,MethodsRetrospective review of electronic records of those receiving an ICPI for melanoma, lung or renal cancer.ResultsOverall, 959 participants were included. In this study, 103 had diabetes at baseline (10.7%). Those with lung cancer had the highest frequency of diabetes; 131 people had hyperglycaemia (defined as at least one glucose ≥11.1 mmol/L) in the year after starting an ICPI. The incidence was 55% in those with diabetes at baseline, and 8.6% in those without baseline diabetes. Among 74 with new-onset hyperglycaemia (without pre-existing diabetes) 76% was attributable to steroid induced diabetes, with 9.5% due to ICPI Induced diabetes resembling type 1 diabetes.ConclusionsHyperglycaemia is common in persons receiving an ICPI for cancer, including 8.6% of those without known diabetes. While much of this is due to glucocorticoid use, care is needed to avoid missing those with ICPI-induced diabetes who are at risk of diabetic ketoacidosis, which is a medical emergency.
AU  - Mulla,K
AU  - Farag,S
AU  - Moore,B
AU  - Matharu,S
AU  - Young,K
AU  - Larkin,J
AU  - Popat,S
AU  - Morganstein,DL
DO  - 10.1111/dme.15053
EP  - 10
PY  - 2023///
SN  - 0742-3071
SP  - 1
TI  - Hyperglycaemia following immune checkpoint inhibitor therapy-Incidence, aetiology and assessment
T2  - Diabetic Medicine
UR  - http://dx.doi.org/10.1111/dme.15053
UR  - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000928841900001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://onlinelibrary.wiley.com/doi/10.1111/dme.15053
UR  - http://hdl.handle.net/10044/1/102827
VL  - 40
ER  -

Download

DrSanjayPopat

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)